Diffuse Large B Cell Lymphoma
Supplemental Studies
Immunohistology and Flow
- B lineage (CD20 or CD79a) positive
- Immunoglobulin variably demonstrable
- More frequent in immunoblastic variant
| CD5 |
10% |
| bcl2 |
30-50% |
| CD10 |
25-50% |
| CD43 |
variable |
| CD30 |
variable |
| Ki67 |
usually >40% |
- T cell / histiocyte rich variant
- Large cells may be missed on flow
- CD30 0-8%
- CD15 0-15%
- EMA 0-60%
- No increase in CD57+ small cell population
Genetic Study
- Gene expression profiling has demonstrated subtypes:
- Germinal center B-like DLBCL
- Activated B-like DLBCL
- Burkitt-like including c-myc
- Some DLBCL with this signature show better response to aggressive chemotherapy targeting Burkitt lymphoma rather than standard DLBCL therapy
- No reliable immunologic panel exists to make these distinctions
